BackTable Urology
Ep. 193 Bladder Cancer Innovations: ESMO 2024 Highlights with Dr. Andrea Apolo
Dr. Bogdana Schmidt
If those patients remain disease-free, right? That's the important caveat because from retrospective data, we know that patients who were T0 after neoadjuvant therapy, who didn't go on to cystectomy, have a recurrence rate of up to 50%, right, if you follow them one to two years. And so obviously that's without adjuvant treatment.
0
💬
0
Comments
Log in to comment.
There are no comments yet.